Ticagrelor Enhances the Cardioprotective Effects of Ischemic Preconditioning in Stable Patients Undergoing Percutaneous Coronary Intervention: the TAPER-S Randomized Study.
Domenico D'AmarioMattia GalliAttilio RestivoFrancesco CanonicoRocco VergalloStefano MigliaroCarlo TraniFrancesco BurzottaCristina AurigemmaRenzo LaboranteEnrico RomagnoliFrancesca FranceseIlaria CeccarelliJosip A BorovacDominick J AngiolilloBarbara TavazziAntonio M LeoneFilippo CreaGiuseppe PattiItalo PortoPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
Ticagrelor enhances the cardioprotective effects of ischemic preconditioning compared with clopidogrel in stable patients with CAD undergoing PCI. Further studies are warranted to fully elucidate the mechanisms through which ticagrelor may exert cardioprotective effects in humans. Clinical Trial Registration: http://www.clinicaltrials.gov. Unique Identifier: NCT02701140.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- coronary artery disease
- ischemia reperfusion injury
- st segment elevation myocardial infarction
- antiplatelet therapy
- cerebral ischemia
- st elevation myocardial infarction
- acute myocardial infarction
- clinical trial
- patients undergoing
- coronary artery bypass grafting
- atrial fibrillation
- subarachnoid hemorrhage
- coronary artery bypass
- oxidative stress
- brain injury
- blood brain barrier
- double blind
- open label
- phase ii
- heart failure
- case control
- phase iii